Clinical Interventions in Aging

open Access Full Text Article

ORIGINAL RESEARCH

The effect of *Polygonum minus* extract on cognitive and psychosocial parameters according to mood status among middle-aged women: a randomized, double-blind, placebo-controlled study

Suzana Shahar¹ Ainor Farahin Aziz² Siti Nur Arina Ismail² Hanis Mastura Yahya² Normah Che Din³ Zahara Abdul Manaf¹ Manal M Badrasawi¹

¹Dietetics Programme, ²Nutritional Sciences Programme, ³Health Psychology Programme, School of Healthcare Sciences, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia



Correspondence: Suzana Shahar Dietetics Programme, School of Healthcare Sciences, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia Tel +60 3 9289 7511 Fax +60 3 2694 7621 Email suzana.shahar@ukm.edu.my **Background:** *Polygonum minus* (PM) or ocally known in Mateysia, as "kesum" is rich in micronutrients and natural antioxidant chargever, its behavior effect on outcome associates with oxidative stress including cognitive function is yet to be discovered. We assessed the efficacy of PM extract (LineMinter) on cognite effunction and psychosocial status among middle-aged women in Klarg Valley of Malaysia.

Methods: A randomized, duble-blind, placebo-controlled trial among 35 healthy middle-aged women was performed, and objects were andomized to receive either 250 mg PM or placebo of 100 mg maltor strin each way taken twice daily for 6 weeks. Subjects were assessed for neuropsychological test, any chosocial status, and anthropometric at baseline, week 3, and week 6. Biomarket over also subtrimed at baseline and week 6.

Result 1.1.5 supplementation of PM showed significant intervention effect on Digit Span test (*P* = 0.05) social functioning domain of 36-Item Short Form Health Survey (*P* < 0.05) among subjects we use the bistorbance. While, among subjects with good mood, PM supplementation implementation Wechsler Abbreviated Scale of Intelligence (WASI) for IQ verbal (*P*=0.016) and Full Scale IQ (F WASI (*P*=0.004). There were no adverse effects reported for the supplementation as indicated using biomarkers, including liver function and clinical symptoms.

nclusion: Supplementation of PM is safe to be consumed for 6 weeks, with potential benefits to a ention, short-term memory, improved quality of life, and mood, as well as IQ.

Keywords: cognitive function, P. minus, psychosocial, women, phytochemicals, quality of life

Introduction

Polygonum minus (PM) or locally known in Malaysia, as "kesum" has been proven to be a potent natural source of antioxidant due to its high antioxidant activity.^{1,2} The PM leaves are used to treat dandruff,³ and to warm up the body, and were believed to be good for blood circulation.⁴ Nutritionally, PM is rich in antioxidant vitamins such as carotenes, retinol equivalents, and vitamin C, α -tocopherol (vitamin E), and minerals such as calcium, phosphorus, iron, sodium, potassium, magnesium, copper, and zinc.⁵ Several studies have reported positive effect of such micronutrients and herbs on mood and cognitive function. For example, a placebo-controlled trial among 300 healthy adults involving 4 weeks administration of a vitamin B complex with vitamin C and minerals (Berocca Calmag[®]) reported that the supplementation improved subjective ratings of stress, anxiety, and psychological well-being.⁶ Similarly, a study was carried out to assess the effects of a similar supplement for 4 weeks among 80 healthy

Clinical Interventions in Aging 2015:10 1505–1520

submit your manuscript | www.dovepress.com

http://dx.doi.org/10.2147/CIA.S86411

© 2015 Shahar et al. This work is published by Dove Medical Press Limited, and Licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions by and the scope of the License are administered by Dove Medical Press Limited, provided the work is properly attributed. Permissions by and the scope of the License are administered by Dove Medical Press Limited, Information on how to request permission may be found at: http://www.dovepress.com/permissions.php men also reported significant attenuated subjective stress and anxiety.⁷ In addition, antioxidant-rich natural herbs such as pine bark extract supplementation for 5 weeks have also been reported to improve cognitive function among middle-aged men, as assessed using spatial working memory and immediate recognition tasks.⁸

Recently, SuperUlam, containing several natural herbs including PM, has been reported to improve cognitive function and mood.9 However, little is known about the beneficial effect of a single extract of PM. Furthermore, the former study⁹ excluded those with poor mood status. According to the World Health Organization (WHO), 12% of Global Disease Burden in 2000 was due to mental and behavioral disorders and it is predicted to increase to 15% by 2020, and indeed, depression causes the largest amount of years lived with disability (YLDs).¹⁰ Thus, this study aimed to determine the effect of natural herbs, ie, PM supplementation on cognitive function and psychosocial parameters among healthy middle-aged working women according to mood status, either poor or good mood. The working middle-aged women were chosen to be the study population, because many studies and cohort stated that women had more anxiety and mood disorders than men^{11–13} and double prevalence of depression compared with men,^{14,15} and this trend can persist un 54 years.¹⁶ Among working adults, a study has reported that the stress score and mood disturbances were high mong middle-aged adults compared with young and lts.17 Ider ac In addition, one study reported that the working have job stresses and higher risk of depressig compa with men in a 6-year cohort study.¹⁸ Generall ental health oblems were shown to increase with age, and there are significant sex differences affecting the increase.¹⁹ Coverally, all the subjects were below the tean age of menopause of 51 years old, in Malaysia.²⁰ For se regions, the study subjects were chosen from mid aged, orking f dales.

Materics an emethods Study description

A randomized, preebo-controlled trial was conducted among 35 healthy middle-aged women recruited from three schools and a governmental organization in Klang Valley, central Malaysia. The inclusion criteria included women, aged 35–55 years and body mass index (BMI) <40.0 kg/m². Subjects with medical conditions (eg, uncontrolled diabetes and kidney problem), had a history of substance or alcohol abuse, smoking, history of major depression, bipolar disorder, pregnant, or lactating, were excluded. Subjects were randomized to either intervention group receiving PM (250 mg of PM) or placebo group (100 mg maltodextrin) twice daily. The study protocol was approved by the Medical Research Ethics Committee of the Universiti Kebangsaan Malaysia, and informed consent was obtained from each subject in accordance with the principles suggested in the Declaration of Helsinki,²¹ and Good Clinical Practice Guidelines.

Intervention (herbal product) and placebo

The supplements capsule containing 250 mg of PM extract (LineMinus[™] Biotropics Malaysized, Selangor, Malaysia), of which the structural formula for he extract standardized based on quercetin 3-genuronide and uercitrin (Table 1). The standardized stract was repare by a water extraction with dried leaves of **P**A to p. extract ratio (1:20) using the unique st- ailable method of aqueous extraction technology.^{22,23} To produce was obtained from a manufacturer in pool manufacture free from Salmonella, Escherit is coli, and Staphylococcus aureus. The lg ins of heavy men, of lead, arsenic, cadmium, and ary contents were less than 1.0, 1.0, 0.2, and 0.05 ppm mer ithin the regulated limits of 10.0, 5.0, 0.3, and 0.5 ppm, and respec vely. Every bottle was closed with inner seal white ons to ensure its safety, prior to consuming.

apsules throughout the intervention period of 6 weeks. The placebo used was a sensory-identical capsule. The inergy, carbohydrate content, and appearance of the placebo

Table I Energy, nutrient, and bioactive profile of kesum (Polygonum minus) and placebo capsules

Constituents (per 100 g)	Placebo	Polygonum minus
Energy ^a		
kJ	386	305
kcal	1,621	1,281
Macronutrients ^a		
Fat (g)	0	0
Carbohydrate (g)	94	67.6
Protein (g)	2.6	8.6
Micronutrients ^{b,c}		
Calcium (mg)	6.3	38.5
Iron (mg)	0.4	1.4
Vitamin A (μg)	0	0
L-Ascorbic acid (mg)	10.6	27.0
α -Tocopherol (mg)	0	0
Bioactive content (%) ^c		
Quercetin-3-glucuronide	-	0.4
Quercitrin	-	0.1

Notes: ^aDetermined by Method of Analysis for Nutritional Labeling, AOAC, 1993.⁵⁴ ^bDetermined by US Environmental Protection Agency (EPA) method revision 2, 1995.⁵⁵ ^cDetermined by high performance liquid chromatography. **Abbreviation:** AOAC, Association of Official Agricultural Chemists. were designed to be similar as the PM. Both groups were required to take two capsules once daily after breakfast, lunch, or dinner. The dosage of two capsules (ie, 500 mg/day) was determined based on a toxicity study on Wistar rats of which no-observed-adverse-effect level of PM extract, at more than 1,000 mg/kg body weight, following oral administration for 8 days.²³

Data collection, outcome measures, and follow-up

A preliminary health screening is performed through a self-administered questionnaire, and a collection of 20 mL fasting venous blood to determine biomarkers including HbA_{1C}, serum lipid, renal profile, liver function, and blood pressure was conducted on 63 subjects. Forty-three subjects were eligible and consented and further assessed for measuring primary outcomes including a neuropsychological tests by using Digit Span,²⁴ Rey Auditory Verbal Learning Test (RAVLT),²⁵ Comprehensive Trail Making Test (CTMT),²⁶ Wechsler Abbreviated Scale of Intelligence (WASI),²⁷ and CNS Vital Sign (CNSVS),²⁸ psychosocial test by using Profile of Mood States (POMS),²⁹ and quality of life using 36-Item Short Form Health Survey (SF-36).³⁰

Their anthropometric measurements including weight were measured using TANITA digital lithium ale HD319 to the nearest 0.1 kg (Tanita Corp n, Tok Japan); height using SECA Leicester rortab Heig Measure (SECA, Hamburg, Germany, and bl was also measured using an automated nitor (Omron e Co., Ltd, 1 HEM 7321-E, OMRON Healt oto, Japan). These measurements were aken a baseline, week 3, and week 6. Blood investigations were convected again at week 6 to determine the time bio parkers as stated previously. On the testing day subjects were advised to limit their saffer ed drip¹ not more than two cups consumption daily. Su mly allocated to either interects w e then **partrolled** group. Subjects were asked to vention or place uking any vitamins, other herbal supplements refrain fre throughout the tudy period. The supplements were provided to the subjects with instructions for consumption listed on the label. Compliance was checked regularly, and 98.3% of the capsules given were consumed by the subjects. A list of symptoms or any side effects experienced by the participant were recorded by the research assistants at each visit.

Compliance checking

Compliance was assessed by performing capsule count at the end of week 3 and week 6. Subjects were reminded by the researcher to take the capsule through a daily phone call or short message service. Subjects were required to record the time of consumption in a dose diary provided.

Statistical analysis

All analyses were performed using SPSS software (v 20.0; IBM Corporation, Armonk, NY, USA). The Shapiro-Wilk test was used to determine data normality. The results were expressed as the mean ± standard deviation (SD) or frequency and percentage, with 95% confidence interval. A two-way repeated measures ANOVA with the new of confounders including age, year of education, how hold income, BMI, and polyphenol intake conducte according to two stratifications, ie, od mood OMS (15) and mood disturbance (POMS) ≥15).⁸ 1 tests e two-tailed at a probability level of 5. 2 distical malysis was performed under a dout -blind photol, photon ing the treatment code was revealed the research only after analysis of all study outcomes comple

kesults

total of 33 subjects, from initially 43 recruited, comp. red the strucy (response rate 87.5%). Three subjects were dropped aue to health problems, and two subjects were lost to thow-up (Figure 1). The mean age of subjects was 45 ± 5.9 and 45 ± 5.5 years, respectively, for both placebo (group A) and PM (group B). All the subjects were Malays, and both groups showed no significant difference with respect to socio-demographic profile (Table 2).

At baseline, there were no significant differences between groups on cognitive and psychosocial status. There was an interaction effect for Digit Span scale score (P < 0.05) among subjects with mood disturbance, of which the mean of Digit Span scale improved among subjects intervention group when compared with placebo (Table 3). The mean of Digit Span scale increased among subjects in PM supplemented group from 9±2.2 at baseline to 10±1.5 at week 3 and maintained at 10±1.9 at week 6. While, among the placebo group, the value increased from 7 ± 1.4 at baseline to 7 ± 1.4 at week 3, but reduced to 9±2.9 at week 6 (Figure 2A). Furthermore, percentage of change of Digit Span continuously increased among the PM supplemented group, but it increased then decreased in the placebo group within subjects with mood disturbance (Figure 2B). Among those with good mood, there was a significant interaction effect for Verbal IQ (P < 0.05) and Full Scale IQ of WASI (P < 0.05) (Table 3). As shown in Figure 3A, within those with good, subjects supplemented with PM, the mean score of Verbal IQ improved




Figure I Study recruitment and flow chart.

from 107 ± 4.4 at baseline to 110 ± 8.6 at week 3 and slightly reduced to 109 ± 6.7 at week 6, but the later value still high than baseline (Figure 3A and B). Such increment was not notably seen in the placebo group. With respect to the Full Scale IQ of WASI, the mean score increased sharply from 105 ± 10.4 at baseline in PM supplemented group to 10 ± 7.4

Table 2 Baseline characteristics of

Baseline	Grou	Gro B	P-value
characteristics	(r s)	(n=17)	
Age (years), mean ± SD	6±6.1	45±4.6	0.829ª
Anthropometric status,			
mean ± SD			
Weight (kg)	67±9.7	67±11.7	0.929ª
Height (cm)	156±5.0	154±5.5	0.412ª
BMI (kg/m ²)		28.2±5.0	0.734ª
Marital status, n			
Married	18 (100.0)	16 (94.1)	0.296 ^b
Single	0 (0.0)	l (5.9)	
Level of education, n (%)			
Secondary school	8 (44.4)	4 (23.5)	0.362 ^b
Certificate/diploma	2 (11.1)	4 (23.5)	
Degree	8 (44.4)	9 (52.9)	
Occupation, n (%)			
Teacher	8 (44.4)	9 (52.9)	0.6I5 ^b
Non-teacher	10 (55.6)	8 (47.1)	
Household income per month (RM), mean \pm SD	7,591±3,904.2	8,251±5,125.1	0.670ª

Notes: aIndependent t-test; bchi-squared test.

Abbreviations: BMI, body mass index; RM, Ringgit Malaysia; SD, standard deviation.

at week abut cloantly reduced to 115 ± 9.4 at week 6, but the neutralue still higher than baseline. However, such a sharp rie was not noted in the placebo group (Figure 4A). Thus, the percentage of change increased by 9% at 3 week and lightly reduced to 7.2% at week 6 in the PM supplemented group, when compared with a slight of increment only between 1% and 2% in the placebo group (Figure 4B). The difference in percentage of change between groups at week 3 was significantly differed.

The time effect was noted in CTMT composite index (P < 0.05) among subjects with mood disturbance and CTMT (Trail 3) (P < 0.05) for subjects with good mood.

With respect to psychosocial, there was a significant interaction effect for SF-36 subscale, ie, social functioning (P < 0.05), of which there was an increased in the mean score among intervention group with mood disturbance from 74±19.4 (baseline) to 89±10.0 (week 3), and 90±9.1 (week 6), when compared with the decrease in placebo group (Table 4 and Figure 5A). Thus, the percentage of change in the PM supplemented group increased by 30% at week 3 and reduced to 15% at week 6, when compared with a reduction by 3% in the placebo group (Figure 5B). However, a significant interaction and time effect was also observed with subjects with mood disturbance in control group showed an improvement in vigor (subscale in

סרמוב	Mood disturbance	bance	Group effect	ffect	Time effect	ect	Intervention effect	tion	Good mood		Group effect		Time effect	ect	Intervention effect	ition
	A (n=7), mean ± SD	B (n=1 ³ mea	P-V	η_{p}^{2}	P-value	η_p^2	P-value	η_p^2	A (n=I I), mean ± SD	B (n=4), mean ± SD	P-value	η_p^2	P-value	η_p^2	P-value	η_p^2
Digit Span ^a scale score	le score				0000			1000							200	
Baseline	7±1.4	9±2.2	0.4/0	V	0.080	0.177	0.03/*	0.224	9±I.8	9±3.7	0.572	0.042	0.701	0.043	0.886	6.0.15
Week 3	II±3.6	I 0±I.5							9±3.I	9±1.4						
Week 6	<u>9±2.9</u>	I0±I.9							I 0±2. I	10±2.5						
RAVLT⁵																
Baseline	53±5.4	50±7.8	0.41	0.053	0.603	0:030	0.313	0.083	48±I I.7	58±8.9	0.965	0.00	0.430	0.086	0.294	0.139
Week 3	55±7.4	48±10.1							46±I 2.I	54±5.4						
Week 6	52±5.4	5 I±7.6	•						48±10.6	54±4.3						
Recall																
Baseline	38±6.4	41±6.9	0.839	0.003	0.071	185	12	0.027	47±I I.6	53±6.2	0.975	0.00	0.104	0.246	0.394	0.110
Week 3	50±5.8	48±6.1							48±I0.9	53±8.2						
Week 6	52±5.4	50±7.8							47±12.2	51±8.5						
CTMT∘																
Trail I								2								
Baseline	38±6.4	4I±6.9	0.839	0.003	0.071	0.1 5	Y	720	39±I I.2	37±7.1	0.431	0.079	0.777	0.031	0.946	0.007
Week 3	50±5.8	48±6.I							48±7.7	47±7.6						
Week 6	52±5.4	50±7.8							, ,	48±10.0						
Trail 2																
Baseline	42±5.7	45±8.4	0.751	0.008	0.961	0.003	0.149	0 26	46±10.1	39±4.1	0.301	0.132	0.207	0.179	0.235	0.165
Week 3	54±14.6	45±4.7							50±9.1	7±5.4						
Week 6	51±11.6	52±12.1							53412.4	4						
Trail 3																
Baseline	41±7.7	42±10.1	0.736	0.009	0.158	0.132	0.168	0.128	42±11.9	4 3±8.3	0.416	0.084	0.029*	0.358	0.236	0.165
Week 3	46±7.4	49±10.5							47±11.6	4 3±8.9						
Week 6	49±11.0	46±7.2							50±10.6	47±8						
Trail 4																
Baseline	39±7.8	40±6.8	0.818	0.004	0.321	0.084	0.349	0.078	42±10.6	€ 1.3	0.554	0.046	0.149	0.212	0.276	0.149
Week 3	43±12.9	44±8.1							44 ±10.2	39 <u>-</u> 3						
Week 6	40±9.4	46±8.6							47±7.6	43±4.c						
Trail 5																
Baseline	46±6.5	45±6.0	0.612	0.020	0.582	0.041	0.917	0.007	4 0±8.4	42±4.3	0.429	0	0.757	0.034	0.062	0.293
Week 3	48±11.7	45±8.0							46±9.6	43±6.9						
Week 6	51+9.8	50±6.4							51±7.3	44±10.1						

week 3, and week 6 according to mood status (mean \pm SD) Table 3 Cognitive function at baseline

	Scale	Mood disturbance	bance.	Group effect	fect	Time effect	ect	Intervention effect	tion	Good mood		Group effect		Time effect	fect	Intervention effect	ntion
		A (n=7), mean ± SD	B (n=I3), mean ± S	P-value	η_p^2	P-value	$\eta_{\rm p}^2$	P-value	$\eta_{\rm p}^2$	A (n=I I), mean ± SD	B (n=4), mean ± SD	P-value		P-value		P-value	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	composite ind Baseline	lex 40+5 4	414	0.947	0.00	0.026*	0.246	0.619	0.036	41+9.8	39+5	0.382	0.097	0.206	0.179	0.284	0.146
6 64:84.4 44:70 7 50:93 44:68 $44:68$ $64:64$ $61:71$ $01:71$	Week 3	48±8.1	45 <u>±</u> 6.1							46 <u>+</u> 9.4	40±6.6						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Week 6		48±7.0							50±9.8	4 4±6.8						
is 012435 0124117 01 017 0171 0171 <th< td=""><td>VASI^d IQ verb</td><td>lac</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	VASI ^d IQ verb	lac															
3 010345 06645 1 100346 009-457 100346 0 015118 009457 100345 00456 0445 0203 0023 0301 0301 0 1124120 115540 115540 0238 0045 0301 0303 0301	Baseline	I 04±9.8	109±11.7	-	-07 -	0.918	0.007	0.568	0.043	4± .4	I07±4.4	0.260	0.177	0.179	0.218	0.016*	0.447
	Week 3	107±8.5	I 06±6.7							I I 0±4.3	II0±8.6						
Optimized (a) Optimized (b) Optimized (c) Optimize	Week 6	108±6.8	I 09±5.7							I I 0±5.5	109±6.7						
3 112412 113460 114413.6 114413.6 114413.6 114413.6 114413.6 114413.6 114413.6 114413.6 114413.6 114413.6 114413.6 114413.6 114413.6 1134.6 1034 0.016 0.017 0.018 0.013 0.013 0.013 0.114.6 0.016 0.016 0.014 0.016	Ası' IV pert. Baseline	ormance IO7+II8	108+97	0.288	0.086	25	0.06	0.390	0.070	113+85	104+185	0.426	0.093	0.082	0.301	0.891	0.016
t_{0} 114±6.8 121±6.0 114±5.6 114±1.5 10410.4 111±5.5 10410.4 0.198 0.124 0.78 0.611 0.175 0.511 0.015 0.614 0.016 0.114 0.016<	Week 3	112±12.2	I I 5±6.0							120±8.3	116±10.3						
Oth Oth Oth Oth OTh ODH OTH ODH III1559 ODH III1559 ODH ODH <th< td=""><td>Week 6</td><td>I I 4±6.8</td><td>121±6.0</td><td></td><td></td><td></td><td>V</td><td></td><td></td><td>120±3.7</td><td>II4±I3.6</td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	Week 6	I I 4±6.8	121±6.0				V			120±3.7	II4±I3.6						
me 10 ± 10 11 ± 3 0.13 0.14 0.14 0.74 0.01 0.71 0.01 <	/ASI' IQ full																
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Baseline	I 06±I 0.4	I I0±I0.I	0.198	0.124	0.794	0.0	75	0.003	I I 5±6.9	105±10.4	0.176	0.245	0.514	0.091	0.004*	0.542
	Week 3	110±10.4	III±5.9						1	117±5.2	II5±9.4						
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Week 6	113±5.7	I 16±5.0							I I 6±4.3	II3±9.0						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	NSVS																
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Visual memo	۵ry ^g															
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Baseline	90 <u>±</u> 20.1	85±8.4	0.591	0.023		0.052	0.383	0.07	60±17.	97±21.0	0.691	0.021	0.642	0.054	0.440	0.09.
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Week 3	83±15.0	88±14.5							78 ±14.6	8 8±9.4						
0 100±15.0 0.286 0.087 0.451 0.059 0.292 0.059 0.2414.5 0.038 0.001 0.551 0.072 0.492 6 104±17.6 9 91±14.5 97±13.8 102±15.0 0.513 0.153 0.072 0.492 6 81±18.7 0.969 0.000 0.133 0.144 0.520 0.049 91±17.4 94±0.6 0.1 0.035 0.153 0.324 6 81±18.7 0.969 0.000 0.133 0.144 0.520 0.049 91±17.4 94±0.6 0.1 0.015 0.154 0.324 7 92±12.1 0.322 0.075 0.746 0.746 0.74 0.746 0.326 0.153 0.324 54 01±12.0 10212.0 0.321 0.324.4 0.146.5 0.146.5 0.1 0.035 0.324 0.324 54 01±12.0 0.322 0.324.4 05±16.5 0.146.5 0.01 0.373 0.033	Week 6	80±22.2	84±18.1					•		85±21.2	93±5.3						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Psychomoto	or speed ^h							0								000
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	baseline	0.11±7.4	100±15.0	0.286	0.08/		4CU.U	7470	CO.0	(9.	5	0.738	0.001	166.0	7/0.0	0.472	0.08
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Week 3	94±10.9	99±14.9							88±19.5	/土14.5						
56 81±18.7 0.369 0.000 0.133 0.144 0.520 0.049 91±17.4 94±0.6 0.11 0.030 0.266 0.153 0.324 0.0 89±15.7 91±11.6 96±13.4 96±13.4 94±0.6 0.013 0.266 0.153 0.324 0.0 89±15.7 91±11.6 94±0.6 0.14.6 96±13.4 94±0.6 0.019 973 0.324 15.1 92±12.1 0.322 0.075 0.581 0.041 0.746 0.022 93±14.0 101±9.7 0.075 0.973 0.903 0.937 16.4 101±12.0 101±12.0 0.322 0.581 0.041 0.746 105±16.5 0.05 0.913 0.903 0.937 103±16.6 107±16.5 106±12.0 0.3412.0 0.14±5.7 0.290 0.138 0.126 0.765 104±15.7 104±15.1 117±20.3 0.138 0.126 0.228 0.765	Week 6	93±15.6	I 04±I 7.6							97±I 3.8	102±15.0						
56 81±18.7 0.569 0.000 0.133 0.144 0.520 0.049 91±17.4 94±16 0.010 0.266 0.153 0.324 0.0 89±15.7 94±16 94±16 94±16 0.01 0.030 0.266 0.153 0.324 0.0 89±15.7 94±16 94±16 94±16 94±16 0.01 0.030 0.266 0.153 0.324 15.1 92±12.1 0.322 0.075 0.581 0.041 0.746 0.022 93±14.0 101±9.1 105 0.01 0.973 0.003 0.937 16.4 101±12.0 101±12.0 103±16.4 105±16.5 103±16.5 0.00 0.973 0.003 0.937 16.4 101±12.0 103±16.5 103±16.6 105±16.5 105±16.5 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.012 0.014 0.014 0.012 0.014 0.014 0.014 0.014 0.014 0.014 0.014 0.	Reaction tim	ie ⁱ															
0 89±15.7 96±13.4 96±13.4 96±9 2.3 91±11.6 714.6 98±11.1 714.6 15.1 92±12.1 0.322 0.075 0.581 0.041 0.746 0.022 93±14.0 101±9.1 05 0.01 0.973 0.033 0.937 16.4 101±12.0 101±12.0 103±16.4 105±16.5 105±16.5 0.03 0.973 0.003 0.937 12.8 101±12.0 103±16.4 105±16.5 106±12.0 106±12.0 0.741 0.009 0.577 0.041 98±13.0 116±7.7 0.290 0.138 0.126 0.765 13.3 104±15.7 104±15.1 117±20.3 117±20.3 117±20.3 0.765 0.765	Baseline	94±I 5.6	81±18.7	0.969	0.000	0.133	0.144	0.520	0.049	91±I7.4	94+1	5	0.030	0.266	0.153	0.324	0.13
2.3 91±11.6 7.14.6 98±11.1 7.14.6 96±11.1 7.14.6 15.1 92±12.1 0.322 0.075 0.581 0.041 0.746 0.022 93±14.0 101±9.1 05 0.0 0.973 0.937 16.4 101±12.0 101±12.0 103±16.4 105±16.5 105±16.5 0.0 0.973 0.003 0.937 12.8 107±11.6 108±6.8 106±12.0 106±12.0 0.591 0.040 0.577 0.041 98±13.0 116±7.7 0.290 0.138 0.126 0.765 1.3 99±13.6 104±15.1 117±20.3 0.14±15.1 117±20.3 0.765	Week 3	95±19.0	89±15.7							96±I 3.4	ه 4.9						
15.1 92±12.1 0.322 0.075 0.581 0.041 0.746 0.022 93±14.0 101±9.1 05 0.0 0.973 0.033 0.937 16.4 101±12.0 101±12.0 103±16.4 105±16.5 105±16.5 0.01 0.973 0.003 0.937 12.8 107±11.6 108±6.8 106±12.0 106±12.0 106±12.0 106±12.0 106±12.0 7.3 99±13.8 0.741 0.090 0.577 0.041 98±13.0 116±7.7 0.290 0.138 0.126 0.765 16.7 104±15.7 104±15.1 117±20.3 116±7.0 0.138 0.126 0.765 0.765	Week 6	97±12.3	91±11.6							98±I I.I	.14.6						
E15.1 92±12.1 0.322 0.075 0.581 0.041 0.746 0.022 93±14,0 101±9,1 0.6 0.973 0.003 0.937 E16.4 101±12.0 103±16.4 105±16.5 103±16.4 105±16.5 0.0 0.973 0.003 0.937 E12.8 107±11.6 107±11.6 108±6.8 106±12.0 106±12.0 0.138 0.126 0.228 0.765 E17.3 99±13.8 0.741 0.009 0.591 0.041 98±13.0 116±7.7 0.290 0.138 0.126 0.765 E16.7 104±15.1 117±20.3 104±15.1 117±20.3 104±15.1 117±20.3	Cognitive fle	sxibility ⁱ															
EI 6.4 101±12.0 103±16.4 105±16.5 EI 2.8 107±11.6 108±6.8 106±12.0 EI 7.3 99±13.8 0.741 0.009 0.577 0.041 98±13.0 116±7.7 0.290 0.138 0.126 0.265 EI 6.7 104±15.7 117±20.3 117±20.3 104±15.1 117±20.3 0.765	Baseline	103±15.1	92±12.1	0.322	0.075		0.041	0.746	0.022	93±I4.0	101±9.	J5	0.0	0.973	0.003	0.937	300.0
E12.8 107±11.6 107±11.6 106±12.0 108±6.8 106±12.0 116±7.7 0.290 0.138 0.126 0.228 0.765 E16.7 104±15.1 117±0.3 104±15.1 115±0.3 104±15.1 115±0.3 104±15.1 117±0.3 104±15.1 117±0.3 104±15.1 117±0.3 10±0.3 115±0	Week 3	I05±I6.4	101±12.0							103±16.4	105±16.5						
E17.3 99±13.8 0.741 0.009 0.591 0.040 0.577 0.041 98±13.0 116±7.7 0.290 0.138 0.126 0.228 0.765 E16.7 104±15.7 104±15.7	Week 6	109±12.8	107±11.6							I 08±6.8	106±12.0						
107±17.3 99±13.8 0.741 0.009 0.591 0.040 0.577 0.041 98±13.0 116±7.7 0.290 0.138 0.126 0.228 0.765 110±16.7 104±15.7 104±15.7	Processing s _l	peed ^k															
110±16.7 104±15.7 104±15.7	Baseline	107±17.3	99±I 3.8	0.741	0.009		0.040	0.577	0.041	98±I 3.0	116±7.7	0.290	0.138	0.126	0.228	0.765	0.035
	Week 3	110±16.7	104±15.7							104±15.1	117±20.3						

D					
	ov	er)r	е	S.S
~	~ .	-r		~	


POMS), when compared with intervention group (P < 0.05 for both) (Table 3). The mean score of vigor decreased from 91±15.7 at baseline in the placebo group to 89±19.7 at week 3 and 88±12.5 at week 6. However, an increment was noted in the intervention group (Figure 6A and B). Among subjects with good mood, only a significant time effect in anger subscale of POMS was found (P < 0.05).

There were no significant interaction effects on anthropometric parameters and blood biomarkers in Tables 5 and 6, respectively. However, there was a significant time effect for weight, BMI, and diastolic block produce; sodium, uric acid, creatinine, total protein, aboulin, total polesterol/high density lipoprotein, and HbA_{1C} \geq 0.05) for all parameters. No significant adverse prects were ported a both placebo and intervention grapps.

Discussi n

To the by ur knowled this is the first clinical trial 1 to evaluate the co hitive and psychosocial effects of PM in an pecifically middle-aged women, with its safety s evidenced by blood biomarkers have also been proven. ecently, interest in products aimed at improving cognitive formance and mood is steadily increasing. However, those products were not supported by scientific evidence. is a trend that most individuals preferred a natural option for improving cognitive function and mood rather than pharmaceutical agents which have been reported to have some side effects.³¹ In one study, Laditka et al found that most of adults used supplements to treat or cure their cognitive problems rather than to prevent them.³² Hence, this study provides scientific evidence of beneficial effect of natural herbs, ie, PM extract in improving cognitive function and psychosocial parameter.


In this study, PM supplementation exerts positive effect on IQ, by 2.1% for verbal and 7.3% for Full Scale IQ of WASI, for subgroup with good mood (POMS \leq 15). PM is a natural herb rich in phytochemicals particularly flavonoid (ie, flavonols, myricetin quercetin, methyl flavonol, and flavones),³³ higher than total flavonoid when compared with other indigenous plants.³⁴ In addition, PM water extract had higher antioxidant activity when comparing with ginger (*Zingiber officinale*) and turmeric (*Curcuma longa*), measured by the total phenolic content, 2,2-diphenyl-11picrylhydrazyl free radical and ferric reducing antioxidant capacities play an important role in delaying or preventing degenerative diseases caused by oxidative damage of living cell components and its free radical scavenging properties




Intelligence

Abbrev

Rey Auditory Verbal Learning Test; SD, standard deviation;





may help to reduce oxidative stress and lipid peroxidation in neuronal membrane, further results in positive effect on memory, cognition, and improved cerebrovascular blood flow.³⁶

Flavonoids and their metabolites are shown to modulate neuronal signaling through tyrosine kinase, phosphoinositide 3-kinase, protein kinase C, and mitogen-activated protein kinase pathways.³⁶ These signaling cascades a also critical for the control of inflammatory processes in the brain, including the activation of microglia onse to cytokines and the induction of inducibil nitric xide synthase and nitric oxide production.³⁷ B ffect pathways, flavonoids can be seen innova e dietary strategies for reducing the effect neuroinfla nation in the brain. In addition, its adributio can also have a

direct impact memory quisi on (learning), conof labile ta memory), and storage solidation (s Tas process through the helpetion of new protein synthesis in . Moreover, flav oids may induce increases in neur cer ral blood flow which eventually give an impact on rformance, or may lead to an increase acu cognitive r sampa¹ ascularization capable of inducing new in hip. ronal growth.³⁸ Thus, PM has the ability to improve including attention and short-term memory, indicated by an improvement in Digit Span by 14.7% as eing seen in this study, among individuals with poor nood or having some degree of mood disturbance. Similar findings were observed in other studies involving natural herbs as neuroprotective supplementations in improving cognitive functions.^{8,9}






Figure 3 (A) The mean score of Verbal IQ of WASI at baseline, week 3, and week 6 among subjects with good mood according to study groups. (B) The percentage of mean change for Verbal IQ from baseline to week 3 and week 6 among subjects with mood disturbance according to study groups. Notes: A, placebo group; B, *Polygonum minus* group. Good mood = POMS \leq 15. Non-significant independent *t*-test. Abbreviations: POMS, Profile of Mood States; WASI, Wechsler Abbreviated Scale of Intelligence.





In this study, the ability of PM supplementation in improving cognition among those with mood disturbance will further improve general well-being such as the social functioning in SF-36. Stress is a risk factor for low physical strength lead to poor well-being. PM composed of quercetin and quercetin-3-glucuronide as its bioactive chemical act as anti-depression agent.³⁹ Moreover, those flavones including hyperin and isoquercitrin had a potential structure f depression.⁴⁰ Quercetin and quercetin-3-glucuronide ere reported to impact the gamma-aminobutyrid recep producing sedation, anxiolytic, or antic vulsiv effects Animal studies showed that quercet, dose increases social interaction, declases obility time, or in animal and minimizes changes in be periments. such as the swim test or orcean mobilization which designed to create anxies and behavio. despair.^{42,43} Thus, it might explain the oility of guercetin in improving social functioning (externor frequency of physical health and the interacting the normal social activiemotions pr ties) in 2 studies showed that quer--36. F ther, h minduced brain corticotropin-releasing cetin **uced** expression (CRF has been implicated in factor (ression).^{42,44} It also attenuates stress-induced anxiety and a increases of plasma corticosterone and adrenocorticotropic hormone.44

In this study, only one of eight domains in POMS, ie, vigor showed significant intervention effect upon supplementation of PM. This beneficial effect was seen in placebo group with mood disturbance. This might be due to differences in subject measurements. Different individuals may have different ways of experiencing emotion. Moods can easily fluctuate and constantly change over period of time and this makes mod charges difficult to measure. Mood can all of by a numerical environmental or external factors (ie, social interactions or stressful life events) and internal factors (ie, excadian rhythms or menstrual cycle in women).⁴⁵ The six distinct mood states in POMS are not laim to capture the entire content domain of mood.⁴⁶ The up of more ojective measurements such as eye-tracking method to monitor emotions based on pupil dilations,⁴⁷ or o, up ing BioM-10 Mood Panel,⁴⁸ a peripheral biomarker set of low vs high mood states are recommended for future studies.

As this is the first study, to the best of our knowledge, to assess the effects of PM extract on cognitive function and psychosocial status, only few comparisons can be made with the existing research in improving cognitive with herbs supplementation. Curcuma longa or turmeric is commonly used to make curries in Asia, has been portrayed as having antioxidant and has the effect of neuron.49 Flavonoid and polyphenols have been long studied for their strong antioxidant capacities, and as scavenging agents for reactive oxygen species thus it have potential role in preventing aging and oxidative stress-related diseases.^{50,51} American ginseng (Panax quinquefolius) has been found to improve working memory performance.⁵² Recently, the product known as SuperUlam has been reported to improve cognitive function and mood after 3 weeks supplementation among middle-aged healthy individuals. SuperUlam is a mixture of several natural plant extracts including PM extract.9 In an animal study, the potent antioxidant in PM extract was capable of entering into and protecting cells from oxidative damage, and produce favorable effects of cognitive function, because the brain has a high level of metabolism and required a high amount of

Scale	Mood disturbance	bance	Group effect	ffect	Time effect	ect	Intervention effect	tion	Good mood		Group effect	fect	Time effect	ect	Intervention effect	Ition
	A (n=7), mean ± SD	B (n=I3), mean ± SD	alue	η_p^2	P-value	η_p^2	P-value	η_p^2	A (n=I I), mean ± SD	B (n=4), mean ± SD	P-value	η_p^2	P-value	$\eta_{\rm p}^2$	P-value	η_p^2
POMS ^a tension	Ц															
Baseline	II±4.5	12±3	763	0.007	0.921	0.006	0.83	0.014	7±2.0	6±3.5	0.843	0.005	0.290	0.143	0.917	0.011
Week 3	8±6.0	8±5.3							I I±6.I	9±7.4						
Week 6	10±3.3	9±5.5							7±6.3	6±I.8						
Depression		-														
Baseline	9±4.9	I5±4.4	, 20	0.0	0.939	0.005	0.809	0.016	3±2.2	<u>3</u> ±2.4	0.533	0.050	0.266	0.152	0.621	0.058
Week 3	6±10.1	7 <u>±</u> 8.1							11±10.5	12±13.5						
Week 6	9±9.2	10土8.6							6±11.5	2.5±2.6						
Anger																
Baseline	I 3±4.6	I3±3.9	0.733	0.009	-24	0.01	909	0.028	5±3.9	6±3.6	0.958	0.000	0.029*	0.375	0.861	0.019
Week 3	6±4.2	9±4.7		•					l I±9.0	9.11±11.6						
Week 6	I2±6.5	10±6.6							7±3.7	5±1.3						
Vigor																
Baseline	I9±7.2	I 9±5.0	0.834	0.004	0.003*	0.35	0.027*	0 7 4 4	20±7.4	21±6.7	0.159	0.232	0.173	0.197	0.864	0.018
Week 3	I7±5.2	I7±6.0							20±4.7	19±1.7						
Week 6	21±5.0	I8±3.9					K		I 9±6.2	22±5.5						
Fatigue																
Baseline	9±2.1	10±3.7	0.270	0.093	0.554	0.044	0.800	0.017	5.2 ±1	5±2.9	0.249	0.162	0.239	0.164	0.918	0.011
Week 3	5±3.4	7±5.2							9±6.4	10±5.7						
Week 6	8±4.5	8±4.6					•		6±6.3	5+4.2						
Confuse																
Baseline	7±2.7	9±1.9	0.194	0.126	0.753	0.022	0.788	0.018	1	4	0.662	0.025	0.373	0.116	0.885	0.015
Week 3	6±3.9	7±2.9							8±3.9	±4.4						
Week 6	7±3.4	7±3.5							6±4.5	5±1.4						
TMD																
Baseline	30±10.8	41±17.2	0.807	0.005	0.648	0.023	0.594	0.030	4±9.0	4土3	د.0	0.118	0.766	0.033	0.877	0.016
Week 3	I 9±27.9	20±28.7							29±31.5	41.7						
Week 6	26±24.9	26±25.3							I3±32.I	2+2						
-36 ^b physica	SF-36 ^b physical functioning															
Baseline	95±6.5	79±19.6	0.356	0.071	0.634	0.024	0.606	0.028	87±12.9	94±4.8	,58	0.0	0.589	0.064	0.379	0.114
Week 3	91±11.0	85±14.5							88±12.9	93±5.0						
Week 6	94±6.1	84±I3.8							90±I I.4	96±4.8						
ole limitatior	Role limitation due to physical health	al health														

						/8
	0.103	0.010	0.064	0.153	0.161	0.052
	0.384	0.815	0.588	0.265	0.245	0.654
	0.014	0.054	0.028	0.037	0.044	0.046
	0.796	0.541	0.799	0.741	0.697	0.684
	0.011	0.059	0.098	0.116	0.022	0.065
	0.771	0.500	0.377	0.335	0.680	0.476
I 00±0.0	l 00±0.0 83±33.3 83±33.3	76±15.5 75±14.7 79±12.5	84±9.8 84±14.2 85±9.5	97±6.3 94±12.5 97±6.3	92±16.3 84±14.2 87±10.3	72 15.5 72 13.5 9
61±42.4	88±30.8 100±0.0 91±30.2	73±16.0 75±17.5 74±21.7	80±11.0 86±9.7 81±15.6	80±21.1 89±13.1 84±16.9	78±19.4 82±14.8 82±20.7	72±21.1 78±17.5
	0.063	0.013	0.070	0.249	4	0 4
	0.396	0.842	0.391	0.02	Ą	0.278
	0.018	0.029	9 2	0.0	0.029	0.038
	0.710	1685	0.671	0.571	0.685	0.606
	0.034	0.183	960.0	0.066	0.232	0.030
	0.51	II.	0.261	0.356	0.069	0.534
Week 6 89±28.3 85±37.6 Role limitation due to emotional problems	72±40.5 82±32.2 95±	58±13.9 68±13.5 65±12.7	70±13.2 76±13.2 73±12.4	74±19.4 89±10.0 90±9.1	63±12.0 77±15.5 70±6.0	62±15.9 71±15.7 69±14.4
89±28.3 n due to emo	90±25.2 95±12.6 90±25.2	e 59±8.4 69±7.5 65±13.5	ell-being 75±9.4 77±5.0 71±19.4	oning 91±15.7 89±19.7 88±12.5	80±19.5 84±13.8 85±19.9	th 68±12.5 69±17.0 69±17.4
Week 6 Role limitatio	Baseline Week 3 Week 6	Energy/tatigue Baseline Week 3 Week 6	Emotional well-being Baseline 75±9.4 Week 3 77±5.0 Week 6 71±19.	Social functioning Baseline 91± Week 3 89± Week 6 88±	Pain Baseline Week 3 Week 6	General health Baseline Week 3 Week 6

Dovepress




Figure 5 (A) The mean score of social functioning of SF-36 at baseline, week 3, and week 6 among subjects with mood disturbance according to study pupe. (B) The percentage of mean change for social functioning of SF-36 from baseline to week 3 and week 6 among subjects with mood disturbance according study pups. (B) The Notes: A, placebo group; B, *Polygonum minus* group. Mood disturbance = POMS > 15. Non-significant independent *t*-test. Abbreviations: POMS, Profile of Mood States; SF-36, 36-Item Short Form Health Survey.

oxygen to do its function which is prone to oxidation by the free radicals.²² Thus, PM extract, along with other natural herbs, has shown to have a neuroprotective effect in human as noted in this study.

The PM extract was safe to use as indicated by no significant changes in liver function, kidney function, and other blood indices in the study subjects, these finding, were supported by findings from a recent study which also reported the safety of supplement contains a subject of herbs, including PM extract on liver and kidley function.⁵³ However, in a retrospective review study on the risk ment of using *Polygonum multiflorma*, on hypofunction,

liver damage was reported in some cases. The safety of this herb may be affected by the type of the species, type of extract, dose, and duration of the intervention. It should be noted that this study documented the safety of another species of *Polygonum* which is PM aqueous extraction using especific cose of 500 mg/day and 6 weeks intervenion period.

fundomized, placebo-controlled, double-blind study design, full 6 weeks of supplementation, blood monitoring at baseline and post-treatment, and multiple assessments of many cognitive functions. However, this study also has




Figure 6 (A) The mean score of vigor at baseline, week 3, and week 6 among subjects with mood disturbance according to study groups. (B) The percentage of mean change for vigor from baseline to week 3 and week 6 among subjects with mood disturbance according to study groups. Notes: A, placebo group; B, *Polygonum minus* group. Mood disturbance = POMS > 15. Non-significant independent *t*-test. Abbreviation: POMS, Profile of Mood States.

Parameter	Group A	Group B	Group ef	fect		Time effe	ect		Intervent	tion effec	t
	(n=18), mean \pm SD	(n=17), mean \pm SD	P-value	$\eta_{_{ m P}}^{_{ m 2}}$	Power	P-value	$\eta_{_{ m p}}^{_{ m 2}}$	Power	P-value	$\eta_{_{ m p}}^{_{ m 2}}$	Power
Weight (kg)											
Baseline	67.3±9.7	66.9±11.7	0.933	0.000	0.051	0.046*	0.089	0.598	0.611	0.015	0.128
Week 3	67.6±9.7	67.4±11.7									
Week 6	67.5±9.8	67.1±11.5									
BMI (kg/m²)											
Baseline	27.7±3.9	28.2±5.0	0.728	0.004	0.063	0.045*	0.090	0.601	0.589	0.016	0.134
Week 3	27.8±3.8	28.4±5.0									
Week 6	27.8±3.9	28.2±5.0									
Fat percentage	2										
Baseline	37.8±5.0	37.3±4.9	0.789	0.002	0.058	0.253	0.041	0.291	0.991	000	0.05 I
Week 3	38.2±4.8	37.7±5.3									
Week 6	38.1±4.5	37.7±4.7									
Systolic (mmH	lg)										
Baseline	118±20.6	117±17.9	0.812	0.002	0.056	0.880	0.00	0.0″	0.878	0.004	0.069
Week 3	9± 6.	117±15.0									
Week 6	117±12.3	117±13.6					K				
Diastolic (mml	Hg)										
Baseline	75±14.7	72±13.7	0.630	0.007	0.076	0.016*	0.1	0.739	0.627	0.014	0.124
Week 3	70±11.2	67±8.3									
Week 6	69±10.4	69±9.3						•			

Table 5 Profile of anthropometri	: parameters at baseline, wee	k 3, and week 6 ac	cording to mood s	status (mean \pm SD)
----------------------------------	-------------------------------	--------------------	-------------------	------------------------

Notes: *Significant at P<0.05 using two-way repeated measures ANOVA. A, placebo grup; B, Polygonum **Abbreviations:** ANOVA, analysis of variance; BMI, body mass index; η_p^2 , partial eta squad; SD, standard

several limitations. For example, although the cognitive ests completed by the subjects were objective, sta dized t of neu based on well-known, validated measured psych logical functioning, several of the subtraction on the Signs battery are relatively brief id may t be sensitive es in neuro enough to detect very subtle c vchological functioning.²⁸ Future research may vish to include objective assessments of contribution such as magnetic resonance imaging

The cognitive asur in this study were administered thus s possible that improvements in 3 weeks apr r learned effects may have perform ce due o prac obscu. 1 the al its to detect any direct effects of study ognitive functioning. Future studies using products arch designs with longer study duration may alternative re. help to clarify the concern. In addition to this, we attribute the lack of statistical significance in our study due to small sample size and short duration of study. Thus, a future higher-powered study is needed to investigate an appropriate number of individuals to generate further statistically significant results with a wide range of population that include different sex and races. Overall, the findings of this study were the first to demonstrate the cognitive function and psychosocial status following supplementation of water effect on blood biomarkers including liver and renal function and also blood sugar and fasting serum lipid. However, the results have to be taken with caution, because not all components of cognitive functions and psychosocial status were shown to be statistically significant. Further research is required to assess the neurocognitive effects of PM in other populations (eg, older individuals and those with cognitive problems).

us groud.

viation.

Conclusion

This study showed that PM supplementation (LineMinusTM) improved both attention and short-term memory and quality of life for social functioning domain among women with mood disturbance in this study. Analysis in a subgroup with good mood indicated that the supplementation improved the IQ of the women in this study. Supplement given at a dosage of 500 mg/day was also proved to be safe with no adverse or toxicity effect on health has assessed using several biomarkers. There is a need to further investigate the beneficial effect of the supplementation among other vulnerable groups such as older adults, for a longer period of study and involving objective measures and biomarkers associated with cognition.

Table 6 Profile of biochemical at baseline and week 6 according to mood status (mean \pm SD)

Parameter	Group A	Group B	Group ef	fect		Time effe	ect		Interven	tion effec	t
	(n=18), mean ± SD	(n=17), mean \pm SD	P-value	$\eta_{_{ m p}}^{_{ m 2}}$	Power	P-value	$\eta_{_{\mathrm{P}}}^{_{2}}$	Power	P-value	$\eta_{_{\mathrm{P}}}^{_{2}}$	Powe
Sodium (mmol/	L)										
Baseline	141±1.6	141±2.1	0.353	0.026	0.150	0.000*	0.323	0.971	0.072	0.095	0.437
Week 6	143±1.9	141±2.6									
Potassium (mm	ol/L)										
Baseline	4.2±0.2	4.3±0.4	0.762	0.003	0.060	0.045*	0.116	0.525	0.083	0.088	0.410
Week 6	4.5±0.5	4.4±0.4									
Urea (mmol/L)											
Baseline	3.7±1.1	3.7±0.8	0.830	0.001	0.055	0.323	0.030	0.164	0.210	0.047	0.237
Week 6	3.7±0.9	3.5±1.0									
Uric acid (µmo	I/L)										
Baseline	302±65.4	303±71.3	0.658	0.006	0.072	0.009*	0.189	0.767	206	0.04	0.240
Week 6	291±69.5	271±57.2									
Creatinine (µm											
Baseline	60±7.6	61±9.1	0.596	0.009	0.081	0.000*	0.511	.000	.991	.000	0.050
Week 6	65±8.8	67±9.9								•	
eGFR (mL/min/		0/2/./									
Baseline	96±15.5	95±19.9	0.856	0.001	0.054	0.000*	516	1.000	5 19	0.000	0.050
Week 6	87±13.0	86±18.2									
Total protein (00210.2							•		
Baseline	78±3.4	79±3.3	0.354	0.026	0.150		0.166	701	0.616	0.008	0.078
Week 6	77±3.0	78±4.6									
Albumin (g/L)	// <u>⊥</u> 5.0	70±1.0									
Baseline	45±2.1	45±2.9	0.953	0.000	0.050	0.112	75	0.355	0.605	0.008	0.080
Week 6	45±1.9	44±3.3						0.000		0.000	
Globulin (g/L)	4 5 ±1.7										
Baseline	33±3.7	35±3.5	0.403	0.020	0.131	071	0.095	0.441	0.640	0.007	0.074
Week 6	33±2.9	33±4.5		0.020			0.070	•••••		01007	
Bilirubin (µmol		JJ_1.J									
Baseline	11±5.9	±4.9	0.7	0 4	0.0	0.083	0.088	0.411	0.330	0.029	0.161
Week 6	10±6.5				0.0	0.005	0.000	0.411	0.550	0.027	0.101
Alkaline phosph		9±3.4									
Baseline	74±20.2	73±14.7	0.709	0.004	0.066	0.407	0.021	0.129	0.395	0.022	0.133
Week 6			0.707	0.004	0.000	0.407	0.021	0.127	0.575	0.022	0.155
	74±19.7	77±22									
GGT (U/L) Baseline	27+21-1	<i>1</i> ±12.9	0	0.010	0.087	0.437	0.018	0.119	0.491	0.014	0.104
	27±21.1		0.5	0.010	0.067	0.437	0.016	0.119	0.471	0.014	0.104
Week 6	27±20.0	35±41 2	•								
Aspartate trans Baseline			0.422	0.020	0.124	0.093	0.083	0.389	0.191	0.051	0.254
Week 6	23±7.1	1 .6.7	0.422	0.020	0.124	0.075	0.065	0.367	0.171	0.031	0.234
		-30.4									
Alanine transar Baseline		201105	0.354	0.027	0.150	0.222	0.045	0.227	0.000	0.084	0.393
	22±115	20±14.5	0.354	0.026	0.150	0.222	0.045	0.227	0.092	0.004	0.373
Week 6		35±40.6									
Total cholester		E 2 2	0.042	0.000	0.051	0/54	0.007	0.072	0 500	0.01.4	0.102
Baseline	5.4±0.	5.3±1.2	0.942	0.000	0.051	0.654	0.006	0.072	0.500	0.014	0.102
Week 6	5.4±0.9	5.4±1.3									
Triglycerides (n	,	0.010.0	0 (72	0.005	0.070	0.200	0.040	0.244	0.4/2	0.017	0.112
Baseline	0.9±0.4	0.9±0.2	0.672	0.005	0.070	0.200	0.049	0.246	0.462	0.017	0.112
Week 6	0.9±0.3	1.0±0.5									
HDL (mmol/L)			0.110	0.075	0.25 (0.100	0.070	0.220	0.272	0.005	0.1.44
Baseline	1.5±0.3	1.7±0.4	0.112	0.075	0.354	0.128	0.069	0.328	0.362	0.025	0.146
Week 6	1.5±0.3	1.7±0.5									
LDL (mmol/L)											
Baseline	3.5±0.9	3.2±1.0	0.429	0.019	0.121	0.545	0.011	0.091	0.872	0.001	0.053
Week 6	3.5±0.8	3.3±1.0									

Table 6 (Continued)

Parameter	Group A	Group B	Group ef	fect		Time effe	ect		Interven	tion effec	:t
	(n=18), mean ± SD	(n=17), mean \pm SD	P-value	$\eta_{_{ m p}}^{_{ m 2}}$	Power	P-value	$\eta_{_{ m p}}^{_{ m 2}}$	Power	P-value	$\eta_{_{ m p}}^{_{ m 2}}$	Power
Total choleste	rol/HDL (mmol/L	_)									
Baseline	3.7±1.1	3.2±0.7	0.142	0.064	0.309	0.019*	0.156	0.670	0.460	0.017	0.112
Week 6	3.8±1.0	3.4±0.9									
HbA _{IC} (%)											
Baseline	5.9±0.8	5.7±0.4	0.325	0.029	0.163	0.000*	0.559	1.000	0.285	0.035	0.184
Week 6	5.6±0.7	5.4±0.3									

Notes: Significant at **P*<0.05 using two-way repeated measures ANOVA. A, placebo group; B, *Polygonum minus* group.

Abbreviations: ANOVA, analysis of variance; eGFR, estimated glomerular filtration rate; GGT, gamma-glutamyl transferase; HbA_{1C} hemoglobin A_{1C}; HDL, high density lipoprotein; LDL, low density lipoprotein; η_p^2 , partial eta squared; SD, standard deviation.

Acknowledgments

This study was funded by Biotropics Malaysia Berhad. The authors thank all participating schools and institution who gave their utmost cooperation in completing the study. The authors also thank all the fieldworkers involved during the data collection period.

Author contributions

SS had access to all data and was involved in the overall study design, interpretation of the data, and revising the manuscript. AFA was involved in interpretation q drafting, and revising the manuscript. NCD, ZAM ana MMB made substantial contributions to conception study design. Both NCD and MMB were al Inv red in planning of statistical analyses and reviring the r nuscrip HMY contributed in conception the ud supervi <u>1</u>g the fieldwork, and revising the produscript. SAI performed statistical analyses, interpresed data, and vised the manuscript. All authors ontributed ward data analysis, drafting and revising the paper and agree be accountable for all aspects of work

Disclos

The autors report no configure of interest in this work.

References

- Qader SW, A. Ila MA, Chua LS, Najim N, Zain MM, Hamdan S. Antioxidant, total, nenolic content and cytotoxicity evaluation of selected Malaysian plants. *Molecules*. 2011;16(4):3433–3443.
- Christapher PV, Parasuraman S, Christina JMA, Asmawi MZ, Vikneswaran M. Review on *Polygonum minus*. Huds, a commonly used food additive in Southeast Asia. *Pharmacognosy Res*. 2015;7(1):1.
- Fazlin A, Ahmad Z, Lim H. Compendium of Medicinal Plants Used in Malaysia. Vol 2. Kuala Lumpur: Herbal Medicine Research Centre, Institute for Medical Research, Aktif Bestari Sdn Bhd; 2002.
- Vikram P, Chiruvella KK, Ripain IHA, Arifullah M. A recent review on phytochemical constituents and medicinal properties of kesum (*Polygo-num minus* Huds.). Asian Pacific J Trop Biomed. 2014;4(6):430–435.
- Ching LS, Mohamed S. Alpha-tocopherol content in 62 edible tropical plants. J Agric Food Chem. 2001;49(6):3101–3105.

- Schlebusch L, Bosch B, Poloffe G, Khenchmidt I, Pill B, Cassimjee M. A double-blind, placebor ontrolled, downe-centre tudy of the effects of an oral multivitation-mineral combination of stress. *S Afr Med J*. 2000;90(12):1216–223.
- Carroll D, Ric C, Storrey, Willems G. The effects of an oral multivitamic combination with calcum, magnesium, and zinc on psychology evel-being in a other young male volunteers: a doubleblind acebo entrolled trial. *csychopharmacology*. 2000;150(2): 220–225.
 - mance after dietary supplementation with a *Pinus radiata* bark extract formulation *Phytother Res.* 2008;22(9):1168–1174.
 - Udani JK. Elects of SuperUlam on supporting concentration and mood: a randomized double-blind, placebo-controlled crossover study. *Evid* and *Complement Alternat Med.* 2013;2013:238454.
- World Health Organization (WHO). The World Health Report 2001 Vental Health: New Understanding, New Hope. Geneva: WHO; 2001.
- Solomon MB, Herman JP. Sex differences in psychopathology: of gonads, adrenals and mental illness. *Physiol Behav.* 2009;97(2): 250–258.
- Oldehinkel AJ, Bouma EM. Sensitivity to the depressogenic effect of stress and HPA-axis reactivity in adolescence: a review of gender differences. *Neurosci Biobehav Rev.* 2011;35(8):1757–1770.
- Seedat S, Scott KM, Angermeyer MC, et al. Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. *Arch Gen Psychiatry*. 2009;66(7):785–795.
- Cyranowski JM, Frank E, Young E, Shear MK. Adolescent onset of the gender difference in lifetime rates of major depression: a theoretical model. *Arch Gen Psychiatry*. 2000;57(1):21–27.
- Bijl RV, de Graaf R, Ravelli A, Smit F, Vollebergh WA. Gender and agespecific first incidence of DSM-III-R psychiatric disorders in the general population. Soc Psychiatry Psychiatr Epidemiol. 2002;37(8):372–379.
- Cairney J, Wade TJ. The influence of age on gender differences in depression. Soc Psychiatry Psychiatr Epidemiol. 2002;37(9):401–408.
- Hamarat E, Thompson D, Zabrucky KM, Steele D, Matheny KB, Aysan F. Perceived stress and coping resource availability as predictors of life satisfaction in young, middle-aged, and older adults. *Exp Aging Res.* 2001;27(2):181–196.
- Clays E, De Bacquer D, Leynen F, Kornitzer M, Kittel F, De Backer G. Job stress and depression symptoms in middle-aged workers – prospective results from the Belstress study. *Scand J Work, Environ Health.* 2007:252–259.
- Bell A. Life-course and cohort trajectories of mental health in the UK, 1991–2008 – a multilevel age-period-cohort analysis. *Soc Sci Med*. 2014;120:21–30.
- Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. *Am J Epidemiol.* 2001;153(9):865–874.

- World Medical Association. *Ethical Principles for Medical Research Involving Human Subjects*. Ferney-Voltaire: World Medical Association; 2000.
- 22. George A, Ng CP, Matthew O, Jensen GS, Wong HJ. In vitro and ex vivo cellular antioxidant protection and cognitive enhancing effects of an extract of *Polygonum minus* Huds (LineminusTM) demonstrated in a Barnes maze animal model for memory and learning. *BMC Complement Alternat Med.* 2014;14(1):161.
- Ming YK, Zulkawi NB, Vandana Kotak C, Choudhary YK. Acute and sub-acute oral toxicity of *Polygonum minus* aqueous extract (Biotropics[®] PM101) in Wistar rats. *Int J Pharm Pharm Sci.* 2013;5(2).
- Groth-Marnat GE. Neuropsychological Assessment in Clinical Practice: A Guide to Test Interpretation and Integration. New York: John Wiley & Sons, Inc.; 2000.
- Rey A. L'examen clinique en psychologie [*The Clinical Examination of Psychology*]. Paris: Presses Universitaires de France; 1964.
- Reynolds CR. Comprehensive Trail Making Test (CTMT). Austin (TX): Pro-Ed; 2002.
- Wechsler D. Wechsler Abbreviated Scale of Intelligence. San Antonio (TX): Psychological Corporation; 1999.
- Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. *Arch Clin Neuropsychol*. 2006;21(7):623–643.
- McNair D. Manual Profile of Mood States. San Diego (CA): Educational and Industrial Testing Service; 1971.
- Brazier JE, Harper R, Jones N, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. *BMJ*. 1992;305(6846):160–164.
- Husain M, Mehta MA. Cognitive enhancement by drugs in health and disease. *Trends Cogn Sci.* 2011;15(1):28–36.
- 32. Laditka JN, Laditka SB, Tait EM, Tsulukidze MM. Use of dietary supplements for cognitive health results of a national survey of Adults in the United States. Am J Alzheimers Dis Other Demen. 20 27(1):55–64.
- Imelda F, Faridah D, Kusumaningrum H. Bacterial inhibition and celleakage by extract of *Polygonum minus* Huds. leaves. *International Res J.* 2014;21(2):553–560.
- Maizura M, Aminah A, Wan Aida W. Total physolic context and antioxidant activity of kesum (*Polygonum minica* ginger *officinale*) and turmeric (*Curcuma longa*) ext. et. Intervences J. 2011; 18(2):529.
- Sumazian Y, Syahida A, Hakiman M, Yuza M. Antioxida, estivities, flavonoids, ascorbic acid and phenory content. Malaysian vegetables. *J Med Plants Res.* 2010;4(10):201–890.
- 36. Spencer JP. Flavonoids and than health: multiple concts underpinned by common mechanisms *Lenes Nut* 2009;4(4):243–250.
 37. Wen L. Pibeiro, P. 775–717, 2007.
- Wen J, Ribeiro R, Zhen Y. Special PKC isoforms regulate LPSstimulated iNOS induction provine micro cal cells. *J Neuroinflam*mation. 2011;8:
- Scholey A. J. drocog nive and superaffects of nutrition and nutraceuticals aper presided at: The 14th Abbott Nutrition Research Conference April 2010 Hambus, OH.
- Pathak L, Agener Y, Dhir A. Natural polyphenols in the management of major depress. *Expert Opin Invest Drugs*. 2013;22(7):863–880.

- Wang WX, Hu XY, Liu P, et al. Studies on screening the anti-depression activities of 10 natural flavonoids like hyperin. *Zhong Cao Yao*. 2007;38(6):900–902.
- Jäger AK, Saaby L. Flavonoids and the CNS. *Molecules*. 2011; 16(2):1471–1485.
- Bhutada P, Mundhada Y, Bansod K, et al. Reversal by quercetin of corticotrophin releasing factor induced anxiety-and depressionlike effect in mice. *Prog Neuropsychopharmacol Biol Psychiatry*. 2010;34(6):955–960.
- Kumar A, Goyal R. Quercetin protects against acute immobilization stress-induced behaviors and biochemical alterations in mice. *J Med Food*. 2008;11(3):469–473.
- 44. Kawabata K, Kawai Y, Terao J. Suppressive effect of quercetin on acute stress-induced hypothalamic–pituitary–adrenal axis response in Wistar rats. *J Nutr Biochem.* 2010;21(5):374–380
- Parkinson B. Changing Moods: The Psychology of X and and Mood Regulation. New York (NY): Addie - Wesley Long, in Limited; 1996.
- Ekkekakis P. The measurement of affect, more and emotion. In: Tenenbaum G, Eklund RC, Kamater reditors. *Measurement in port and Exercise Psychology*. Champeren, IL: Hyper Kinetics. po12:321–332.
- 47. Valenza G, Scilingo EP, extended C Nervous System Dynamics for Mood and Emotion State Reconstition: Symplect Advances in Data Acquisition, Sign. Processing as Classic Lation. New York: Springer Science & Prone, Media; 2013.
- Kéri S, Szaoó C, Kennen O. Blood biomarkers of depression track clinical phanges during a mitive-behavioral therapy. *J Affect Disord*. 201,164:118–122.
- 49. 1, T-P, Chiam P-C, Lee Ť, Chua H-C, Lim L, Kua E-H. Curry nsumption and opgnitive function in the elderly. *Am J Epidemiol.* 16;164(9):898-106.
- 50. Ha. on RE, Sho A, Fagan AM, et al. Pomegranate juice decreases amylou and improves behavior in a mouse model of Alzheimer's incase. *Neurobiol Dis.* 2006;24(3):506–515.
 - Gun, ge JM, Halliwell B. Invited review free radicals in disease processes: a compilation of cause and consequence. *Free Radic Res.* 1993;19(3):141–158.
 - . Scholey A, Ossoukhova A, Owen L, et al. Effects of American ginseng (*Panax quinquefolius*) on neurocognitive function: an acute, randomised, double-blind, placebo-controlled, crossover study. *Psychopharmacology*. 2010;212(3):345–356.
- 53. Udani JK, George AA, Musthapa M, Pakdaman MN, Abas A. Effects of a proprietary freeze-dried water extract of *Eurycoma longifolia* (Physta) and *Polygonum minus* on sexual performance and well-being in men: a randomized, double-blind, placebo-controlled study. *Evid Based Complement Alternat Med.* 2014;2014:179529.
- Sullivan DM, Carpenter DE, editors. *Methods of Analysis for Nutrition Labeling*. Arlington, VA: AOAC INTERNATIONAL; 1993:33–83.
- 55. US Environmental Protection Agency (EPA). Determination of Organic Compounds in Drinking Water by Liquid-Solid Extraction and Capillary Column Gas Chromatography/Mass Spectrometry. Revision 2.0. Method 525.2. 1995. Available from: http://water.epa.gov/scitech/ methods/cwa/upload/Methods-for-the-Determination-of-Organic-Compounds-in-Drinking-Water.pdf. Accessed July 1, 2014.

Clinical Interventions in Aging

Publish your work in this journal

Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings. This journal is indexed on PubMed Central, MedLine,

Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal

Dovepress

CAS, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress. com/testimonials.php to read real quotes from published authors.